Health Catalyst, Inc. (HCAT) is a leading provider of data and analytics technology and services to healthcare organizations committed to improving clinical, financial, and operational outcomes. Memorialized in corporations including Nasdaq, the company has been a trailblazer in delivering tangible results by drawing usable insights from the vast amounts of healthcare data.
Established in 2008 and headquartered in Salt Lake City, Utah, Health Catalyst's major focus is on transforming healthcare through structured and systematic utilization of data. Its data operating system (DOS™) is a breakthrough engineering approach that combines the features of data warehousing, clinical data repositories, and health information exchanges in a single, common-sense technology platform. This enables healthcare institutions to harness the power of raw data, bolstering their decision-making processes and enhancing patient care.
Health Catalyst serves a diverse portfolio of clients that span over 50 million patients in the US alone. They offer a broad suite of services ranging from technology solutions to analytics accelerators, and professional services. Technological solutions include a wide array of analytical applications, system integrations, quality metrics, and more. Health Catalyst also aids in professional services such as application implementation, healthcare analytics, and agile development.
Adopting a cloud-based, software-as-a-service (SaaS) delivery model, Health Catalyst essentially orchestrates agile healthcare operations by facilitating seamless data-management, fostering real-time access, and encouraging collaboration across facets of the healthcare ecosystem.
One of the key milestones for the company was its initial public offering in 2019. The successful IPO not only established a significant moment for the company but also reiterated the growing importance of data-driven insights in modern healthcare. Since then, Health Catalyst has continued to innovative and robustly expand its client base which attests to the lucrative future of data analytics in healthcare.
In an era marked by escalating healthcare costs and complexities, Health Catalyst's vision is to ultimately drive massive, sustained improvements in healthcare outcomes. To achieve this future, the company is building and maintains long-term transformation partnerships with healthcare leaders who are passionate about improving patient care with their commitment to thought leadership, technology, and analytics at the forefront. All of this creates exciting opportunity for growth and helps in fostering a culture that is conducive to the company's sustained success.
To sum up, Health Catalyst Inc. (HCAT) is a pioneering company that uses advanced analytics and data to transform healthcare. Their innovative platforms and services support healthcare institutions in achieving improved patient outcomes at reduced costs, underlining the immense potential of data-driven insights in this sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Despite a recent 48.7% surge in stock price over six months, analysts recommend caution for Health Catalyst (HCAT) due to declining billings, low gross margins, and long customer acquisition payback periods. The company's fundamentals are considered shaky, making its optically cheap valuation risky. Instead, the article suggests looking for more robust investment opportunities.
Analysts have revised Health Catalyst's (HCAT) fair value down from approximately US$2.10 to US$1.83 per share, reflecting increased caution due to growth risks, churn, and divestitures. While some analysts maintain a Neutral stance, others have downgraded the stock to Hold and reduced price targets. This shift highlights concerns about the durability of growth in its health technology offerings and ongoing transformation efforts.
Health Catalyst has appointed Simeon Kohl as its new Chief Executive Officer and President, effective September 14, 2026. Kohl previously led Performant Healthcare through a strategic transformation culminating in its sale for approximately $670 million. Current CEO Ben Albert will transition to Chief Business Officer, having overseen the company's shift towards AI-forward healthcare intelligence and the divestiture of Vitalware to strengthen its balance sheet.
Health Catalyst, Inc. announced the grant of 2,747,385 restricted stock units (RSUs) to Simeon Kohl, their newly appointed Chief Executive Officer and President, effective September 14, 2026. These inducement awards are part of the Company's 2026 Employment Inducement Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). A portion of the RSUs will vest in September 2027, with the remainder vesting quarterly thereafter, contingent on Mr. Kohl's continued employment.
Health Catalyst has appointed Simeon Kohl as its new CEO and President, effective September 14, 2026. Kohl, who has over 20 years of healthcare experience and previously led Performant Healthcare, will succeed Ben Albert. Albert will transition to Chief Business Officer, focusing on strategic priorities alongside Kohl, who is expected to enhance growth and operational performance for the AI-forward healthcare intelligence company.